Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022.
H.C. Wainwright Global Investment Conference fireside chat details:
|Date:||Wednesday, September 14th, 2022|
|Time:||4:00 pm Eastern Time|
|Webcast:||The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.|
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Released September 9, 2022